Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors

NCT01614795 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01614795
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01614795 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
June 18, 2012
Completion date
April 1, 2014
Enrollment
46 (actual)
Sites
76

Conditions

As the registry lists them; a condition with its own page is linked.

childhood alveolar soft part sarcoma, childhood angiosarcoma, childhood epithelioid sarcoma, childhood fibrosarcoma, childhood gliosarcoma, childhood leiomyosarcoma, childhood liposarcoma, childhood malignant peripheral nerve sheath tumor, childhood synovial sarcoma, previously treated childhood rhabdomyosarcoma, recurrent childhood rhabdomyosarcoma, recurrent childhood soft tissue sarcoma, recurrent ewing sarcoma/peripheral primitive neuroectodermal tumor, recurrent osteosarcoma, rhabdomyosarcoma